Botanix Pharmaceuticals Limited (BXPHF) Price & Analysis

2 Followers

BXPHF Stock Chart & Stats

$0.01

$0.02(142.31%)

At close: Jul 29 4:00 PM EDT

$0.01

$0.02(142.31%)

Day’s Range― - ―

52-Week Range$0.01 - $0.13

Previous CloseN/A

Volume114.00K

Average Volume (3M)5.62K

Market Cap

$41.36M

Enterprise Value$34.48

Total Cash (Recent Filing)$36.63M

Total Debt (Recent Filing)$14.74M

Price to Earnings (P/E)―

Beta-0.86

Next Earnings

Mar 03, 2027

EPS Estimate

>-0.01

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.03

Shares Outstanding2,736,612,800

10 Day Avg. Volume2,450

30 Day Avg. Volume5,620

Financial Highlights & Ratios

PEG Ratio0.02

Price to Book (P/B)0.65

Price to Sales (P/S)1.19

P/FCF Ratio-0.64

Enterprise Value/Market Cap<0.01

Enterprise Value/Revenue<0.01

Enterprise Value/Gross Profit>-0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$0.41

Price Target Upside3994.31% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)>-0.01

Revenue Forecast (FY)$44.02M

Bulls Say, Bears Say

Bulls Say

Rapid Commercial Adoption And Revenue GrowthStrong prescription growth and accelerating net revenue indicate meaningful product adoption after launch. Sustained uptake can expand Botanix’s commercial base and improve operating leverage as Sofdra gains physician and payer acceptance.

Long Product Life And Sizable Addressable MarketPatent protection through 2040 provides a long exclusivity runway for commercialization and potential cash generation. The sizable patient population supports continued growth beyond the initial launch period if adoption and reimbursement expand.

Scalable Fulfillment And Potential Margin ImprovementA high-performing fulfillment platform can support larger prescription volumes and additional products without equivalent development costs. Qualifying an alternate API supplier could also improve gross margins and reduce dependence on one source.

Bears Say

Persistent Losses And Unstable ProfitabilityTop-line growth has not yet translated into durable profitability. Deep gross losses and continuing operating losses suggest the business remains dependent on substantial investment, leaving execution and margin improvement critical to long-term viability.

Large Ongoing Cash BurnThe scale of operating cash outflows materially exceeds current internal cash generation. Unless revenue growth and margins improve substantially, Botanix may need recurring external financing, limiting flexibility and increasing funding dependence.

Funding And Single-source Supply RiskThe partially funded raise leaves capital availability contingent on further execution and approval. At the same time, sole-source API dependence and committed purchases create supply continuity and liquidity risks while an alternate supplier is qualified.

Botanix Pharmaceuticals Limited News

Botanix Pharm: Strong Sofdra Adoption and Margin Upside Support Buy Rating with Unchanged $1 Price Target

Botanix Pharmaceuticals Limited, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis...

2d ago

Botanix files updated ASX corporate governance statement for 2026

Botanix Pharmaceuticals Limited ( ($AU:BOT) ) just unveiled an announcement. Botanix Pharmaceuticals has lodged its updated corporate governance...

2d ago

Botanix Revenue Surges on Sofdra Launch as Loss Narrows

Botanix Pharmaceuticals Limited ( ($AU:BOT) ) just unveiled an update. Botanix Pharmaceuticals reported a sharp increase in revenue...

2d ago

Botanix Issues 14 Million Unquoted Performance Rights Under Incentive Plan

Botanix Pharmaceuticals Limited ( ($AU:BOT) ) has provided an update. Botanix Pharmaceuticals has notified the market of the...

14d ago

Botanix Pharmaceuticals Adds 2.3 Million Shares to ASX Quotation

An announcement from Botanix Pharmaceuticals Limited ( ($AU:BOT) ) is now available. Botanix Pharmaceuticals has applied for quotation...

15d ago

Botanix Pharmaceuticals Updates Market on Lapsing of 3.25 Million ASX Options

Botanix Pharmaceuticals Limited ( ($AU:BOT) ) just unveiled an announcement. Botanix Pharmaceuticals has notified the market of the...

25d ago

Botanix: Sofdra Launch Momentum and Revenue Recovery Support Unchanged $1 Price Target and Buy Rating

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Botanix Pharmaceuticals Limited,...

1M ago

Botanix boosts Sofdra sales, tightens costs and fortifies IP as cash position strengthens

Botanix Pharmaceuticals Limited ( ($AU:BOT) ) just unveiled an announcement. Botanix Pharmaceuticals reported strong growth for the June...

1M ago

Botanix Seeks ASX Quotation for 10.3 Million New Shares

An update from Botanix Pharmaceuticals Limited ( ($AU:BOT) ) is now available. Botanix Pharmaceuticals has applied for quotation...

3M ago

Botanix Securities Lapse Trims Potential Share Dilution

An update from Botanix Pharmaceuticals Limited ( ($AU:BOT) ) is now available. Botanix Pharmaceuticals has notified the market...

3M ago

BXPHF FAQ

What was Botanix Pharmaceuticals Limited’s price range in the past 12 months?

Botanix Pharmaceuticals Limited lowest stock price was $0.01 and its highest was $0.13 in the past 12 months.

What is Botanix Pharmaceuticals Limited’s market cap?

Botanix Pharmaceuticals Limited’s market cap is $41.36M.

When is Botanix Pharmaceuticals Limited’s upcoming earnings report date?

Botanix Pharmaceuticals Limited’s upcoming earnings report date is Mar 03, 2027 which is in 187 days.

How were Botanix Pharmaceuticals Limited’s earnings last quarter?

Botanix Pharmaceuticals Limited released its earnings results on Aug 26, 2026. The company reported -$0.007 earnings per share for the quarter, the consensus estimate of -$0.007 by $0.

Is Botanix Pharmaceuticals Limited overvalued?

According to Wall Street analysts Botanix Pharmaceuticals Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Botanix Pharmaceuticals Limited pay dividends?

Botanix Pharmaceuticals Limited does not currently pay dividends.

What is Botanix Pharmaceuticals Limited’s EPS estimate?

Botanix Pharmaceuticals Limited’s EPS estimate is >-0.01.

How many shares outstanding does Botanix Pharmaceuticals Limited have?

Botanix Pharmaceuticals Limited has 2,736,612,800 shares outstanding.

What happened to Botanix Pharmaceuticals Limited’s price movement after its last earnings report?

Botanix Pharmaceuticals Limited reported an EPS of -$0.007 in its last earnings report, expectations of -$0.007. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Botanix Pharmaceuticals Limited?

Currently, no hedge funds are holding shares in BXPHF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Botanix Pharmaceuticals Limited Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-17.91%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Botanix Pharmaceuticals Limited

Botanix Pharmaceuticals Limited, an Australian enterprise, is dedicated to the discovery and advancement of novel dermatological and antimicrobial therapeutic agents. The company's central mission involves pioneering innovative treatments for widespread skin conditions and various infections. Its robust developmental portfolio showcases several key assets: Sofpironium Bromide, which has successfully completed Phase 3 clinical studies for managing primary axillary hyperhidrosis; BTX 1503, a transdermal gel designed to tackle severe acne in both adults and teenagers, having concluded Phase II trials; BTX 1801, which has progressed through Phase IIb clinical investigations for infections caused by Staphylococcus aureus (including its methicillin-resistant variant); BTX 1702, currently undergoing Phase IIb clinical evaluation for papulopustular rosacea; and BTX 1204A, targeting atopic dermatitis. Established in 1984, Botanix Pharmaceuticals operates from its headquarters in Leederville, Australia.

Botanix Pharmaceuticals Limited (BXPHF) Earnings & Revenues

Historic Earnings Reports

BXPHF Stock 12 Month Forecast

Average Price Target

$0.41

▲(3994.31% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","1":"$1","-1":"-$1","-0.5":"-$0.5","0.5":"$0.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":0.7183,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$0.72</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.40943100000000004,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$0.41</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.100562,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$0.10</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.5,0,0.5,1],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.015,0.0691,0.1232,0.1773,0.2314,0.28550000000000003,0.3396,0.39370000000000005,0.44780000000000003,0.5019,0.556,0.6101000000000001,0.6642,{"y":0.7183,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.015,0.045340846153846155,0.07568169230769231,0.10602253846153846,0.1363633846153846,0.1667042307692308,0.19704507692307693,0.22738592307692307,0.25772676923076926,0.2880676153846154,0.3184084615384616,0.3487493076923077,0.37909015384615385,{"y":0.40943100000000004,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.015,0.02158169230769231,0.028163384615384614,0.03474507692307692,0.04132676923076923,0.04790846153846154,0.05449015384615384,0.06107184615384615,0.06765353846153846,0.07423523076923078,0.08081692307692308,0.08739861538461538,0.09398030769230768,{"y":0.100562,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.141,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.1,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.106,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.09,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.078,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.079,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.085,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.043,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.04,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.019,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.022,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.011,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.015,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >

Similar Stocks

ACR

Acrux

―

CUV

Clinuvel Pharmaceuticals

―

SPL

Starpharma Holdings Limited

―

ZLD